CHLORHEXIDINE ALCOHOL FREE MOUTHWASH

Country: Կանադա

language: անգլերեն

source: Health Canada

active_ingredient:

CHLORHEXIDINE GLUCONATE

MAH:

EURO-PHARM INTERNATIONAL CANADA INC

ATC_code:

A01AB03

INN:

CHLORHEXIDINE

dosage:

0.12%

pharmaceutical_form:

MOUTHWASH

composition:

CHLORHEXIDINE GLUCONATE 0.12%

administration_route:

BUCCAL

units_in_package:

500ML/4L

prescription_type:

Prescription

therapeutic_area:

MISCELLANEOUS ANTI-INFECTIVES

leaflet_short:

Active ingredient group (AIG) number: 0107629007; AHFS:

authorization_status:

CANCELLED POST MARKET

authorization_date:

2021-06-03

SPC

1
PRODUCT MONOGRAPH
PR
CHLORHEXIDINE ALCOHOL FREE
Chlorhexidine Gluconate Oral Rinse, 0.12% w/v House Standard
ANTIGINGIVITIS ORAL RINSE
EURO-PHARM INTERNATIONAL CANADA INC.
9400 BOUL. LANGELIER
MONTREAL, QUEBEC
H1P 3H8
DATE OF PREPARATION:
JULY 6, 2017
CONTROL NO.: 205962
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
5
DRUG INTERACTIONS
...................................................................................................
5
DOSAGE AND ADMINISTRATION
...............................................................................
5
OVERDOSAGE
.................................................................................................................
6
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 7
STORAGE AND STABILITY
...........................................................................................
8
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 8
PART II: SCIENTIFIC INFORMATION
................................................................................
9
PHARMACEUTICAL INFORMATION
...........................................................................
9
CLINICAL TRIALS
.........................................................................................................
10
TOXICOLOGY
...................................................................................